| Bioactivity | Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3]. | |||||||||
| Invitro | Lipoxin A4 (LXA4) inhibits the expression of IL-6 and IL-8 in NHEKs[2]. Lipoxin A4 downregulates the expression of cyclin D1[2].Lipoxin A4 also suppresses the ERK1/2 phosphorylation and NF-kB-p65 nuclear translocation of NHEKs[2].LXA4 (100 nM; preincubation for 30 minutes)inhibits the proliferation of NHEKs with or without stimulating by LPS (10 μg/mL)[2]. LXA4 pretreatment (100 nM for 30 minutes) downregulates the LPS-induced secretion and expression of HMGB1 in keratinocytes[1]. Cell Proliferation Assay[2] Cell Line: | |||||||||
| Name | Lipoxin A4 | |||||||||
| CAS | 89663-86-5 | |||||||||
| Formula | C20H32O5 | |||||||||
| Molar Mass | 352.47 | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|